O-012The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer. (2nd July 2019) - Metges, J; François, E; Shah, M; Adenis, A; Enzinger, P; Kojima, T; Muro, K; Bennouna, J; Hsu, C; Moriwaki, T; Kim, S; Lee, S; et al.